Supplementary Material for: Early Treatment with Human Albumin Solution in Continuous Renal Replacement Patients

Aims: To study the impact of early human albumin solution (HAS) in continuous renal replacement therapy (RRT) patients. Methods: Analysis of Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial data. Results: Of 1,464 patients, 500 (34%) received early albumin. These patients had higher illness severity scores, greater use of mechanical ventilation, and 90-day mortality (51 vs. 41%; p p = 0.62). On Cox proportional hazards regression, with standardized inverse probability of treatment weighting, early albumin was not associated with increased mortality (hazard ratio [HR]: 1.23, 95% CI: 0.97–1.55; p = 0.09) or recovery to RRT independence (HR: 0.92, 95% CI: 0.78–1.10; p = 0.38). Conclusions: Early albumin was administered to one-third of RENAL trial patients and in those with greater illness severity. Early albumin was not independently associated with mortality risk or rate of recovery to RRT independence.

研究目的：探讨早期人血白蛋白（human albumin solution, HAS）对连续性肾脏替代治疗（continuous renal replacement therapy, RRT）患者的影响。
研究方法：对正常水平与升高水平连续性肾脏替代治疗随机评估（Randomized Evaluation of Normal versus Augmented Level, RENAL）试验的RRT相关数据进行分析。
研究结果：1464例受试患者中，500例（34%）接受了早期人血白蛋白治疗。此类患者的疾病严重程度评分更高，机械通气使用率更高，且90天死亡率更高（51% vs 41%；P=0.62）。经标准化治疗加权逆概率校正的Cox比例风险回归分析显示，早期人血白蛋白治疗与患者死亡率升高无独立相关性（风险比[HR]：1.23，95%置信区间[CI]：0.97~1.55；P=0.09），亦与患者恢复至脱离RRT治疗的状态无独立相关性（HR：0.92，95%CI：0.78~1.10；P=0.38）。
研究结论：RENAL试验中有三分之一的受试患者接受了早期人血白蛋白治疗，且此类患者的疾病严重程度更高。早期人血白蛋白治疗与患者的死亡风险或脱离RRT治疗的恢复速率并无独立相关性。